Abstract 378P
Background
Until now there had been a lack of comprehensive data from extensive samples to assess the therapeutic potential of inetetamab (a novel recombinant humanized anti-HER2 monoclonal antibody) in metastatic breast cancer (MBC) patients who had previously received trastuzumab. This study aimed to provide a broad and in-depth analysis of the real-world efficacy and safety of inetetamab in the specific populations.
Methods
A multicenter retrospective real-world study collected clinicopathological data from HER2-positive metastatic breast cancer patients (n = 500) between Jan 2022 and Oct 2023. Progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) of patients who received inetetamab therapy were estimated. Adverse events (AEs) were classified based on the Common Terminology Criteria for Adverse Events.
Results
In the overall cohort, the PFS was 7 months. The median number of treatment was three. The ORR was 28.6%, and the DCR was 89.2%. Meanwhile, patients who received a combination treatment regime of inetetamab + tyrosine kinase inhibitors (TKIs) + chemotherapy achieved the most prolonged PFS of 9.0 months and the higher ORR of 29.3%. Cox multivariate analysis revealed that PFS was associated with distant lymph nodes metastasis and previous TKIs treatment. The most common treatment-related AEs were neutropenia and leukopenia, which were generally well-tolerated.
Conclusions
Inetetamab demonstrated promising efficacy and safety in HER2-positive MBC patients who had prior exposure to trastuzumab, particularly in combination with TKIs and chemotherapy.
Clinical trial identification
NCT06305702.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
385P - A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Presenter: David Page
Session: Poster session 15
388P - Anlotinib or bevacizumab combined with chemotherapy for the second-line HER-2 negative metastatic breast cancer: A retrospective cohort study
Presenter: jin xiang
Session: Poster session 15
390P - SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Presenter: Maria Cona
Session: Poster session 15
391P - Real-world activity of sacituzumab govitecan for metastatic breast cancer
Presenter: Stefania Morganti
Session: Poster session 15
392P - Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Adam Brufsky
Session: Poster session 15
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15